Tier 2 — strong

Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine

Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G
The Journal of clinical endocrinology and metabolism 2008 93(7):2559-2565

Bibliography

PubMed
PMID 18397984
Funding
Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample116 adults with diabetes and dyslipidemia
InterventionBerberine 1 g/day versus placebo
Duration3 months
EndpointsFasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability

What the study showed, in plain terms

Berberine improved glycemic and lipid measures relative to placebo in adults who had both diabetes and dyslipidemia. The trial measured metabolic surrogates rather than diabetic complications.

Key findings

  • HbA1c in the berberine arm changed from 7.5% to 6.6%.
  • The authors also assessed insulin sensitivity with a clamp method.

What this study can and cannot tell us

Brief follow-up and a selected clinical population limit generalization to healthy people.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Citation network

Articles citing this research paper

12 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified